Cargando…

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia

Paliperidone palmitate every three months (PP3M) is expected to facilitate patient’s treatment compliance and satisfaction. The objective here was to compare PP3M treatment compliance and satisfaction, effectiveness and tolerability, with paliperidone palmitate-monthly (PP1M) in patients with severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Miranda, Juan J., Díaz-Fernández, Silvia, De Berardis, Domenico, López-Muñoz, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036785/
https://www.ncbi.nlm.nih.gov/pubmed/33915786
http://dx.doi.org/10.3390/jcm10071408
_version_ 1783676991666388992
author Fernández-Miranda, Juan J.
Díaz-Fernández, Silvia
De Berardis, Domenico
López-Muñoz, Francisco
author_facet Fernández-Miranda, Juan J.
Díaz-Fernández, Silvia
De Berardis, Domenico
López-Muñoz, Francisco
author_sort Fernández-Miranda, Juan J.
collection PubMed
description Paliperidone palmitate every three months (PP3M) is expected to facilitate patient’s treatment compliance and satisfaction. The objective here was to compare PP3M treatment compliance and satisfaction, effectiveness and tolerability, with paliperidone palmitate-monthly (PP1M) in patients with severe schizophrenia. A 24-month prospective, open-label study of patients with severe schizophrenia treated with PP3M after at least 2 years of stabilization with PP1M (n = 84) was carried out. Treatment satisfaction was assessed with the Treatment Satisfaction Questionnaire for Medication (TSQM) and with a Visual Analogue Scale (VAS). Effectiveness was measured with psychiatric hospital admissions and the Clinical Global Impression-Severity (CGI-S) scale. Tolerability assessments included laboratory tests, weight and adverse effects. Reasons for treatment discontinuation were recorded. CGI-S significantly improved after 24 months. Three patients changed back to PP1M due to adverse effects, and four were hospitalized. There were neither abandoning nor significant changes in weight or biological parameters, and lower incidence of side effects, with PP3M treatment. TSQM and VAS scales increased. No differences were found related to doses. Apart from somewhat improvement in treatment adherence, effectiveness, and tolerability, patients with severe schizophrenia lengthy treated with PP1M showed more satisfaction with PP3M, even those who needed high doses to get clinical stabilization.
format Online
Article
Text
id pubmed-8036785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80367852021-04-12 Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia Fernández-Miranda, Juan J. Díaz-Fernández, Silvia De Berardis, Domenico López-Muñoz, Francisco J Clin Med Article Paliperidone palmitate every three months (PP3M) is expected to facilitate patient’s treatment compliance and satisfaction. The objective here was to compare PP3M treatment compliance and satisfaction, effectiveness and tolerability, with paliperidone palmitate-monthly (PP1M) in patients with severe schizophrenia. A 24-month prospective, open-label study of patients with severe schizophrenia treated with PP3M after at least 2 years of stabilization with PP1M (n = 84) was carried out. Treatment satisfaction was assessed with the Treatment Satisfaction Questionnaire for Medication (TSQM) and with a Visual Analogue Scale (VAS). Effectiveness was measured with psychiatric hospital admissions and the Clinical Global Impression-Severity (CGI-S) scale. Tolerability assessments included laboratory tests, weight and adverse effects. Reasons for treatment discontinuation were recorded. CGI-S significantly improved after 24 months. Three patients changed back to PP1M due to adverse effects, and four were hospitalized. There were neither abandoning nor significant changes in weight or biological parameters, and lower incidence of side effects, with PP3M treatment. TSQM and VAS scales increased. No differences were found related to doses. Apart from somewhat improvement in treatment adherence, effectiveness, and tolerability, patients with severe schizophrenia lengthy treated with PP1M showed more satisfaction with PP3M, even those who needed high doses to get clinical stabilization. MDPI 2021-04-01 /pmc/articles/PMC8036785/ /pubmed/33915786 http://dx.doi.org/10.3390/jcm10071408 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fernández-Miranda, Juan J.
Díaz-Fernández, Silvia
De Berardis, Domenico
López-Muñoz, Francisco
Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
title Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
title_full Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
title_fullStr Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
title_full_unstemmed Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
title_short Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
title_sort paliperidone palmitate every three months (pp3m) 2-year treatment compliance, effectiveness and satisfaction compared with paliperidone palmitate-monthly (pp1m) in people with severe schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036785/
https://www.ncbi.nlm.nih.gov/pubmed/33915786
http://dx.doi.org/10.3390/jcm10071408
work_keys_str_mv AT fernandezmirandajuanj paliperidonepalmitateeverythreemonthspp3m2yeartreatmentcomplianceeffectivenessandsatisfactioncomparedwithpaliperidonepalmitatemonthlypp1minpeoplewithsevereschizophrenia
AT diazfernandezsilvia paliperidonepalmitateeverythreemonthspp3m2yeartreatmentcomplianceeffectivenessandsatisfactioncomparedwithpaliperidonepalmitatemonthlypp1minpeoplewithsevereschizophrenia
AT deberardisdomenico paliperidonepalmitateeverythreemonthspp3m2yeartreatmentcomplianceeffectivenessandsatisfactioncomparedwithpaliperidonepalmitatemonthlypp1minpeoplewithsevereschizophrenia
AT lopezmunozfrancisco paliperidonepalmitateeverythreemonthspp3m2yeartreatmentcomplianceeffectivenessandsatisfactioncomparedwithpaliperidonepalmitatemonthlypp1minpeoplewithsevereschizophrenia